• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, August 3, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Immunology

Study reveals protein that dials immune responses up and down

Bioengineer by Bioengineer
June 1, 2016
in Immunology
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

La Jolla, Calif., May 25, 2016 — Research led by scientists at the Sanford Burnham Prebys Medical Discovery Institute (SBP) has identified a new regulator of immune responses. The study, published recently in Immunity, sheds new light on why T cells fail to clear chronic infections and eliminate tumors. The findings open the door for a new approach to modulating T cell responses in many clinical settings, including infections, autoimmune diseases, and tumors that are unresponsive to currently available therapies.

“We discovered that a protein on the surface of T cells, P-selectin glycoprotein ligand-1 (PSGL-1), acts as a negative regulator of T cell function,” said Linda Bradley, Ph.D., professor in the Immunity and Pathogenesis Program. “PSGL-1 has the broad capacity to dampen T cell signals and promote the exhaustion of T cells in viral and tumor mouse models.”

T cells are the immune cells responsible for recognizing and destroying specific invaders, whether from outside the body (viruses or bacteria) or within (cancer). Their activity is highly tunable–signals from other cells adjust T cell responses to counteract the invasion. However, sometimes those responses fall short, such as in chronic viral infections and cancers that thwart immune responses by inducing T cell dysfunction.

The recent emergence of drugs that block immune checkpoints has provided a new, improved approach to treating certain cancers such as lung cancer and melanoma. Immune checkpoints act as brakes for T cells, restraining the immune system from self-attack and preventing autoimmune diseases. Inhibitors of checkpoints remove these brakes, and unleash the immune system to tackle these cancers–in some cases extending survival by years.

Bradley and her lab found that PSGL-1 is required to increase levels of immune checkpoints to allow T cell inhibition. When PSGL-1 is missing, the brakes are off, and T cells remain active longer than they normally would.

“Blocking PSGL-1 may enhance the immune response to cancer and chronic viral infections such as hepatitis. In contrast, activating PSGL-1 may be a way to inhibit immune responses that could potentially be used to treat autoimmune diseases, such as rheumatoid arthritis, psoriasis, multiple sclerosis and lupus,” said Bradley.

Bradley’s study was performed using mice engineered to lack PSGL-1. These mice could completely eradicate lymphocytic choriomeningitis virus (LCMV) infections, which normally last months.

“Total clearance of LCMV is rare,” Bradley commented. “When we saw that, we knew PSGL-1 was crucial for limiting immune responses.”

The research group then looked at whether this lack of an immune brake would impact cancer by injecting the same mice with melanoma cells. The resulting tumors grew much slower than they do in normal mice, showing PSGL-1 regulates T cell responses in general.

“We’ve received a lot of interest from pharmaceutical companies wanting to explore the clinical potential of our findings,” added Bradley.

“PSGL-1 inhibitors could provide another tool in the arsenal against cancer, and benefit the many patients who don’t respond to the currently available checkpoint inhibitors.”

The Bradley lab is now looking for synergies with other types of anti-cancer drugs. Because T cells may not be able to reach all tumor cells, combining immune therapies with drugs that kill the cancer more directly could work better than either approach alone.

###

This research was performed in collaboration with scientists at the University of Massachusetts Medical School and Yale School of Medicine. Funding for the study was provided by the National Institutes of Health and the Melanoma Research Foundation.

About SBP

Sanford Burnham Prebys Medical Discovery Institute (SBP) is an independent nonprofit medical research organization that conducts world-class, collaborative, biological research and translates its discoveries for the benefit of patients. SBP focuses its research on cancer, immunity, neurodegeneration, metabolic disorders and rare children’s diseases. The Institute invests in talent, technology and partnerships to accelerate the translation of laboratory discoveries that will have the greatest impact on patients. Recognized for its world-class NCI-designated Cancer Center and the Conrad Prebys Center for Chemical Genomics, SBP employs about 1,100 scientists and staff in San Diego (La Jolla), Calif., and Orlando (Lake Nona), Fla. For more information, visit us at SBPdiscovery.org or on Facebook at facebook.com/SBPdiscovery and on Twitter @SBPdiscovery.

Media Contact

Susan Gammon, Ph.D.
[email protected]
858-795-5012
@sbpdiscovery

http://www.sbpdiscovery.org/

The post Study reveals protein that dials immune responses up and down appeared first on Scienmag.

Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

UMass Amherst grad student awarded fellowship for food allergy research

July 23, 2021
IMAGE

Less-sensitive COVID-19 tests may still achieve optimal results if enough people tested

July 22, 2021

Public trust in CDC, FDA, and Fauci holds steady, survey shows

July 20, 2021

USC study shows male-female differences in immune cell function

July 19, 2021
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    49 shares
    Share 20 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Weight-Adjusted Waist Index Predicts Breast Cancer

Institutional Factors Impacting Cervical Cancer Guideline Compliance

Bright Hybrid Excitons Boost Scalable X-ray Scintillators

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.